Arnold Cha, MD
Family Medicine · Vancouver, WANPI 1811320179
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 25.3% of the total. Reporting peaked in 2021 at $863 and has fallen 88.4% since, to $100 in 2024.
Across 51 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$285
- Boehringer Ingelheim$274
- AstraZeneca$112
- Amgen$72
- Amarin Pharma, Inc.$57
- Medtronic$45
- plus $281 from 11 others
What the payments were for
- Food & beverage$1,127100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $285 |
| Boehringer Ingelheim | 9 | $274 |
| AstraZeneca | 3 | $112 |
| Amgen | 3 | $72 |
| Amarin Pharma, Inc. | 3 | $57 |
| Medtronic | 1 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Organon | 3 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $38 |
| Pfizer | 2 | $28 |
| Evofem Biosciences, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Abbott | 1 | $21 |
| Merck | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Philips North America LLC | 1 | $13 |
How this compares
$1,127 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 22 | $538 |
| Oxycodone Hcl | 20 | $274 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Vancouver
- Rick JacksonVancouver$28K
- Bernard StupskiVancouver$17K
- Donald BenzVancouver$14K
- Noel GuzmanVancouver$9K
- Kevin HatfieldSeattle$527K
- Marta KazymyraBlaine$222K
- Donella YoungDavenport$175K
- Robert McIntyreSeattle$107K
- James MorenBellingham$106K
- Marshall BrownPasco$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.